Acadia Healthcare Q2 revenue beats in inpatient growth but costs bite
Reuters2026/07/28 20:24
Overview
US behavioral healthcare provider's Q2 revenue was flat yr/yr, beating analyst expectations
Adjusted EBITDA for Q2 slightly beat analyst consensus
Company added 240 licensed beds from newly constructed facilities in Q2
Outlook
Acadia Healthcare raises 2026 revenue guidance to $3.40-$3.45 bln from $3.37-$3.45 bln
Company lifts 2026 adjusted EBITDA forecast to $590-$615 mln from $580-$615 mln
Acadia Healthcare increases 2026 operating cash flow outlook to $350-$400 mln from $285-$325 mln
Result Drivers
SUPPLEMENTAL PAYMENT TIMING - Flat revenue and same-facility revenue were impacted by the timing of supplemental payment program revenue in Florida and Tennessee
HIGHER OPERATING COSTS - Adjusted EBITDA declined due to a $39.3 mln increase in professional and general liability costs, including a $28.6 mln reserve adjustment, and higher salaries and benefits
VOLUME GROWTH IN ACUTE INPATIENT - Acute inpatient volumes rose 5.5%, driven by expanded capacity from new and existing facilities
Company press release: ID:nBw86FNda
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Revenue |
Beat |
$865.84 mln |
$844.23 mln (10 Analysts) |
Q2 Net Income |
|
$12.26 mln |
|
Q2 Adjusted EBITDA |
Slight Beat* |
$149.20 mln |
$148.18 mln (11 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities services peer group is "buy"
Wall Street's median 12-month price target for Acadia Healthcare Company Inc is $31.50, about 3.1% below its July 27 closing price of $32.50
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty
July 28 - Centene flags weakening Medicaid membership, shares fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why Buy XRP Now? 21Shares Names 4 Exact Reasons, Including SEC Verdict

Ethena expands USDe to TRON as ENA eyes recovery above key resistance
Wall Street Adds Another Lululemon (LULU.US) Short Seller! After an 81% Plunge from its Peak, BMO Warns Tough Times Are Still Ahead
BMO Capital Markets believes that Lululemon’s turnaround from losses will not be swift or easy. The sportswear company is handing over market share to competitors, and the decline in sales continues to deepen.

PENGU Drops 7.5% as Memecoin Selloff Puts Key Support at Risk
